AbbVie today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging bispecific antibody, and lenalidomide, compared to rituximab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results